LEUKOSIGHT, INC.

Biotech · Private

Fcγ Receptor Activating Nanoparticles (FcγRANP) for macrophage reprogramming in autoimmune disease treatment

Grants
$225K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Treating collagen-induced arthritis (CIA) with immunoregulatory nanoparticles$179,502
Federal grantDepartment of Health and Human Services · Phase I · Treating collagen-induced arthritis (CIA) with immunoregulatory nanoparticles$45,497
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1330Mozart Therapeutics——
1331Knudra Diagnostics——
1332NURAVAX, INC.——
1333LEUKOSIGHT, INC.——
1334JT PHARMACEUTICALS, INC.——
1335YUMA THERAPEUTICS CORPORATION——
1336MINUTIA INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 1
  • POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAMEapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.